NEW YORK (Reuters Health) – The response rate to high-dose pulsed intravenous glucocorticoid therapy is about 80% for patients with active Graves’ orbitopathy, German clinicians report. However, they caution that potential for major adverse effects necessitates careful patient selection.
Writing in the...